Adjunctive, Low-dose tPA in Primary PCI for STEMI

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2017
STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.
Epistemonikos ID: ca51be55fa2beab8de2e05eac081c2ea89188842
First added on: Dec 20, 2022